This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.
Quick Summary ChatGPT thinks UiPath stock could drift lower over the next 60 days, projecting a move toward roughly $16.20 by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback